X4 Pharmaceuticals Inc. (XFOR)
X4 Pharmaceuticals Statistics
Share Statistics
X4 Pharmaceuticals has 5.79M shares outstanding. The number of shares has increased by 0.49% in one year.
| Shares Outstanding | 5.79M |
| Shares Change (YoY) | 0.49% |
| Shares Change (QoQ) | 0.82% |
| Owned by Institutions (%) | 49.7% |
| Shares Floating | 4.4M |
| Failed to Deliver (FTD) Shares | 153.18K |
| FTD / Avg. Volume | 206.86% |
Short Selling Information
The latest short interest is 8.8M, so 5.07% of the outstanding shares have been sold short.
| Short Interest | 8.8M |
| Short % of Shares Out | 5.07% |
| Short % of Float | 5.13% |
| Short Ratio (days to cover) | 4.73 |
Valuation Ratios
The PE ratio is -3545.03 and the forward PE ratio is -11.86. X4 Pharmaceuticals's PEG ratio is 52.62.
| PE Ratio | -3545.03 |
| Forward PE | -11.86 |
| PS Ratio | 51920.76 |
| Forward PS | 0.1 |
| PB Ratio | 5994.01 |
| P/FCF Ratio | -1011.69 |
| PEG Ratio | 52.62 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for X4 Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.12.
| Current Ratio | 3.41 |
| Quick Ratio | 3.33 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | -0.1 |
| Debt / FCF | -0.02 |
| Interest Coverage | -4.15 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $17.88K |
| Profits Per Employee | $-261.89K |
| Employee Count | 143 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.28 |
Taxes
| Income Tax | 310K |
| Effective Tax Rate | -0.83% |
Stock Price Statistics
The stock price has increased by -88.3% in the last 52 weeks. The beta is 0.58, so X4 Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.58 |
| 52-Week Price Change | -88.3% |
| 50-Day Moving Average | 8.31 |
| 200-Day Moving Average | 15.64 |
| Relative Strength Index (RSI) | 21.47 |
| Average Volume (20 Days) | 74.05K |
Income Statement
In the last 12 months, X4 Pharmaceuticals had revenue of 2.56M and earned -37.45M in profits. Earnings per share was -0.01.
| Revenue | 2.56M |
| Gross Profit | 1.76M |
| Operating Income | -36.4M |
| Net Income | -37.45M |
| EBITDA | -27.58M |
| EBIT | -28.37M |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
The company has 55.7M in cash and 2.66M in debt, giving a net cash position of 53.04M.
| Cash & Cash Equivalents | 55.7M |
| Total Debt | 2.66M |
| Net Cash | 53.04M |
| Retained Earnings | -515.36M |
| Total Assets | 146.45M |
| Working Capital | 79.3M |
Cash Flow
In the last 12 months, operating cash flow was -130.9M and capital expenditures -326K, giving a free cash flow of -131.23M.
| Operating Cash Flow | -130.9M |
| Capital Expenditures | -326K |
| Free Cash Flow | -131.23M |
| FCF Per Share | -0.02 |
Margins
Gross margin is 68.83%, with operating and profit margins of -1423.58% and -1464.61%.
| Gross Margin | 68.83% |
| Operating Margin | -1423.58% |
| Pretax Margin | -1452.48% |
| Profit Margin | -1464.61% |
| EBITDA Margin | -1078.45% |
| EBIT Margin | -1423.58% |
| FCF Margin | -5132.07% |
Dividends & Yields
XFOR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for XFOR is $90, which is 2274.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $90 |
| Price Target Difference | 2274.7% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Apr 28, 2025. It was a backward split with a ratio of 1:30.
| Last Split Date | Apr 28, 2025 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | -3.29 |
| Piotroski F-Score | 0 |